COVID-19 疫苗相关性血管炎:系统综述。

IF 2.3 Q2 MEDICINE, GENERAL & INTERNAL
SAGE Open Medicine Pub Date : 2024-08-30 eCollection Date: 2024-01-01 DOI:10.1177/20503121241261165
Aseel Abuhammad, Maram Albandak, Mohammed Ayyad, Eman Refayeh, Basema Qawasma, Shaima Hour, Yazan Abu Thraiee, Zaid A Sowaity, Osama Dukmak, Afnan W M Jobran, Laith Alamleh
{"title":"COVID-19 疫苗相关性血管炎:系统综述。","authors":"Aseel Abuhammad, Maram Albandak, Mohammed Ayyad, Eman Refayeh, Basema Qawasma, Shaima Hour, Yazan Abu Thraiee, Zaid A Sowaity, Osama Dukmak, Afnan W M Jobran, Laith Alamleh","doi":"10.1177/20503121241261165","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Post-COVID-19 vaccine-associated vasculitis stands as one of the most serious side effects attributed to COVID-19 vaccines. This complication encompasses diverse manifestations which vary in presentation and severity. Moreover, it can impact patients across all age groups, with a notably elevated incidence in the elderly. This systematic review seeks to review and evaluate the spectrum of vasculitis manifestations linked to COVID-19 vaccination.</p><p><strong>Methods: </strong>A systematic review of the literature was done by searching through PubMed, Google Scholar, and Scopus up to October 2022. Articles including data about sex, age at diagnosis, vasculitis clinical manifestations, type of vaccination, most commonly used investigations, comorbid medical conditions, treatments, and clinical outcomes were included in the final analysis. Furthermore, vasculitis flare-ups post-vaccination were considered part of this review.</p><p><strong>Results: </strong>A total number of 117 studies describing 158 patients developing vasculitis following COVID-19 vaccination were included in the final analysis. Among the patients who developed vasculitis, the most administered type of vaccination was the mRNA vaccine subtype (<i>n</i> = 103), followed by the viral vector vaccines (<i>n</i> = 42) and inactivated viral vaccines (<i>n</i> = 10). On the other hand, about 38% of vasculitis-related symptoms occurred after the administration of the first dose of the vaccine and 37% occurred after taking the second dose. The skin (60.7%) and the kidneys (27.8%) were the most affected organs and complete remission was achieved in 111 patients (70%), while partial remission occurred in 11% of the patient population.</p><p><strong>Conclusion: </strong>COVID-19 vaccine-induced vasculitis is a rare occurrence associated with COVID-19 vaccines. It generally presents a favorable prognosis and outcomes for the vast majority of patients, ultimately leading to full remission within days. This review emphasizes the notion that the advantages of COVID-19 vaccines outweigh the potential risks, particularly for individuals with compromised immune systems.</p>","PeriodicalId":21398,"journal":{"name":"SAGE Open Medicine","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11367607/pdf/","citationCount":"0","resultStr":"{\"title\":\"COVID-19 vaccine-associated vasculitis: A systematic review.\",\"authors\":\"Aseel Abuhammad, Maram Albandak, Mohammed Ayyad, Eman Refayeh, Basema Qawasma, Shaima Hour, Yazan Abu Thraiee, Zaid A Sowaity, Osama Dukmak, Afnan W M Jobran, Laith Alamleh\",\"doi\":\"10.1177/20503121241261165\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Post-COVID-19 vaccine-associated vasculitis stands as one of the most serious side effects attributed to COVID-19 vaccines. This complication encompasses diverse manifestations which vary in presentation and severity. Moreover, it can impact patients across all age groups, with a notably elevated incidence in the elderly. This systematic review seeks to review and evaluate the spectrum of vasculitis manifestations linked to COVID-19 vaccination.</p><p><strong>Methods: </strong>A systematic review of the literature was done by searching through PubMed, Google Scholar, and Scopus up to October 2022. Articles including data about sex, age at diagnosis, vasculitis clinical manifestations, type of vaccination, most commonly used investigations, comorbid medical conditions, treatments, and clinical outcomes were included in the final analysis. Furthermore, vasculitis flare-ups post-vaccination were considered part of this review.</p><p><strong>Results: </strong>A total number of 117 studies describing 158 patients developing vasculitis following COVID-19 vaccination were included in the final analysis. Among the patients who developed vasculitis, the most administered type of vaccination was the mRNA vaccine subtype (<i>n</i> = 103), followed by the viral vector vaccines (<i>n</i> = 42) and inactivated viral vaccines (<i>n</i> = 10). On the other hand, about 38% of vasculitis-related symptoms occurred after the administration of the first dose of the vaccine and 37% occurred after taking the second dose. The skin (60.7%) and the kidneys (27.8%) were the most affected organs and complete remission was achieved in 111 patients (70%), while partial remission occurred in 11% of the patient population.</p><p><strong>Conclusion: </strong>COVID-19 vaccine-induced vasculitis is a rare occurrence associated with COVID-19 vaccines. It generally presents a favorable prognosis and outcomes for the vast majority of patients, ultimately leading to full remission within days. This review emphasizes the notion that the advantages of COVID-19 vaccines outweigh the potential risks, particularly for individuals with compromised immune systems.</p>\",\"PeriodicalId\":21398,\"journal\":{\"name\":\"SAGE Open Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2024-08-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11367607/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"SAGE Open Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/20503121241261165\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"SAGE Open Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/20503121241261165","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

目标:COVID-19 疫苗接种后相关血管炎是 COVID-19 疫苗最严重的副作用之一。这种并发症包括多种表现形式,其表现形式和严重程度各不相同。此外,它可影响所有年龄组的患者,尤其是老年人的发病率较高。本系统综述旨在回顾和评估与接种 COVID-19 疫苗相关的血管炎表现:通过搜索 PubMed、Google Scholar 和 Scopus,对截至 2022 年 10 月的文献进行了系统综述。最终分析纳入的文章包括性别、诊断年龄、血管炎临床表现、疫苗接种类型、最常用的检查方法、合并症、治疗方法和临床结果等数据。此外,接种疫苗后脉管炎复发也被视为本次综述的一部分:结果:共有 117 项研究纳入了最终分析,这些研究描述了 158 名接种 COVID-19 疫苗后出现血管炎的患者。在发生血管炎的患者中,接种最多的疫苗类型是 mRNA 疫苗亚型(103 例),其次是病毒载体疫苗(42 例)和灭活病毒疫苗(10 例)。另一方面,约 38% 的血管炎相关症状发生在接种第一剂疫苗后,37% 发生在接种第二剂疫苗后。皮肤(60.7%)和肾脏(27.8%)是受影响最严重的器官,111名患者(70%)的病情完全缓解,11%的患者病情部分缓解:结论:COVID-19疫苗诱发的血管炎是一种与COVID-19疫苗相关的罕见病。结论:COVID-19 疫苗诱发的血管炎是与 COVID-19 疫苗相关的罕见病症,一般来说,绝大多数患者的预后和治疗效果良好,最终可在数天内完全缓解。本综述强调 COVID-19 疫苗的优势大于潜在风险,尤其是对于免疫系统受损的患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
COVID-19 vaccine-associated vasculitis: A systematic review.

Objectives: Post-COVID-19 vaccine-associated vasculitis stands as one of the most serious side effects attributed to COVID-19 vaccines. This complication encompasses diverse manifestations which vary in presentation and severity. Moreover, it can impact patients across all age groups, with a notably elevated incidence in the elderly. This systematic review seeks to review and evaluate the spectrum of vasculitis manifestations linked to COVID-19 vaccination.

Methods: A systematic review of the literature was done by searching through PubMed, Google Scholar, and Scopus up to October 2022. Articles including data about sex, age at diagnosis, vasculitis clinical manifestations, type of vaccination, most commonly used investigations, comorbid medical conditions, treatments, and clinical outcomes were included in the final analysis. Furthermore, vasculitis flare-ups post-vaccination were considered part of this review.

Results: A total number of 117 studies describing 158 patients developing vasculitis following COVID-19 vaccination were included in the final analysis. Among the patients who developed vasculitis, the most administered type of vaccination was the mRNA vaccine subtype (n = 103), followed by the viral vector vaccines (n = 42) and inactivated viral vaccines (n = 10). On the other hand, about 38% of vasculitis-related symptoms occurred after the administration of the first dose of the vaccine and 37% occurred after taking the second dose. The skin (60.7%) and the kidneys (27.8%) were the most affected organs and complete remission was achieved in 111 patients (70%), while partial remission occurred in 11% of the patient population.

Conclusion: COVID-19 vaccine-induced vasculitis is a rare occurrence associated with COVID-19 vaccines. It generally presents a favorable prognosis and outcomes for the vast majority of patients, ultimately leading to full remission within days. This review emphasizes the notion that the advantages of COVID-19 vaccines outweigh the potential risks, particularly for individuals with compromised immune systems.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
SAGE Open Medicine
SAGE Open Medicine MEDICINE, GENERAL & INTERNAL-
CiteScore
3.50
自引率
4.30%
发文量
289
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信